957 related articles for article (PubMed ID: 31035238)
21. Preclinical Studies of PROTACs in Hematological Malignancies.
Fuchs O; Bokorova R
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
[TBL] [Abstract][Full Text] [Related]
22. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
23. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
Liang Y; Nandakumar KS; Cheng K
Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
[TBL] [Abstract][Full Text] [Related]
24. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
25. PROTACs: New method to degrade transcription regulating proteins.
Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
[TBL] [Abstract][Full Text] [Related]
26. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
Belcher BP; Ward CC; Nomura DK
Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
[TBL] [Abstract][Full Text] [Related]
27. Progress on small-molecule proteolysis-targeting chimeras.
Huang W; Wang B; Zhang Z; Zhang C; Zeng S; Shen Z
Future Med Chem; 2019 Oct; 11(20):2715-2734. PubMed ID: 31571504
[TBL] [Abstract][Full Text] [Related]
28. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
29. Recent Advances in PROTAC Technology Toward New Therapeutic Modalities.
Yokoo H; Naganuma M; Oba M; Demizu Y
Chem Biodivers; 2022 Nov; 19(11):e202200828. PubMed ID: 36124821
[TBL] [Abstract][Full Text] [Related]
30. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.
Irshad Khan MZ; Nazli A; Pan YL; Chen JZ
Curr Med Chem; 2023; 30(14):1576-1622. PubMed ID: 35927805
[TBL] [Abstract][Full Text] [Related]
31. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
32. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.
Buckley DL; Raina K; Darricarrere N; Hines J; Gustafson JL; Smith IE; Miah AH; Harling JD; Crews CM
ACS Chem Biol; 2015 Aug; 10(8):1831-7. PubMed ID: 26070106
[TBL] [Abstract][Full Text] [Related]
33. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
[TBL] [Abstract][Full Text] [Related]
34. Development of targeted protein degradation therapeutics.
Chamberlain PP; Hamann LG
Nat Chem Biol; 2019 Oct; 15(10):937-944. PubMed ID: 31527835
[TBL] [Abstract][Full Text] [Related]
35. Bifunctional Molecules beyond PROTACs.
Conway SJ
J Med Chem; 2020 Mar; 63(6):2802-2806. PubMed ID: 32157887
[TBL] [Abstract][Full Text] [Related]
36. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
37. Ubiquitin proteasome system in immune regulation and therapeutics.
Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
[TBL] [Abstract][Full Text] [Related]
38. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
39. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
40. Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation.
Márquez-Cantudo L; Ramos A; Coderch C; de Pascual-Teresa B
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]